Regulus Therapeutics Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Jay Hagan
Chief executive officer
US$2.6m
Total compensation
| CEO salary percentage | 23.9% |
| CEO tenure | 7yrs |
| CEO ownership | 0.09% |
| Management average tenure | 4.8yrs |
| Board average tenure | 7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$31m |
| Dec 31 2023 | US$3m | US$616k | -US$30m |
| Sep 30 2023 | n/a | n/a | -US$29m |
| Jun 30 2023 | n/a | n/a | -US$28m |
| Mar 31 2023 | n/a | n/a | -US$29m |
| Dec 31 2022 | US$1m | US$598k | -US$28m |
| Sep 30 2022 | n/a | n/a | -US$29m |
| Jun 30 2022 | n/a | n/a | -US$30m |
| Mar 31 2022 | n/a | n/a | -US$29m |
| Dec 31 2021 | US$2m | US$568k | -US$28m |
| Sep 30 2021 | n/a | n/a | -US$22m |
| Jun 30 2021 | n/a | n/a | -US$15m |
| Mar 31 2021 | n/a | n/a | -US$16m |
| Dec 31 2020 | US$2m | US$552k | -US$16m |
| Sep 30 2020 | n/a | n/a | -US$19m |
| Jun 30 2020 | n/a | n/a | -US$23m |
| Mar 31 2020 | n/a | n/a | -US$21m |
| Dec 31 2019 | US$2m | US$536k | -US$19m |
| Sep 30 2019 | n/a | n/a | -US$22m |
| Jun 30 2019 | n/a | n/a | -US$27m |
| Mar 31 2019 | n/a | n/a | -US$36m |
| Dec 31 2018 | US$2m | US$520k | -US$49m |
| Sep 30 2018 | n/a | n/a | -US$55m |
| Jun 30 2018 | n/a | n/a | -US$60m |
| Mar 31 2018 | n/a | n/a | -US$68m |
| Dec 31 2017 | US$2m | US$475k | -US$72m |
Compensation vs Market: Jay's total compensation ($USD2.57M) is above average for companies of similar size in the German market ($USD385.73K).
Compensation vs Earnings: Jay's compensation has increased whilst the company is unprofitable.
CEO
Jay Hagan (54 yo)
7yrs
Tenure
US$2,574,323
Compensation
Mr. Joseph P. Hagan, also known as Jay, served as Independent Director of Zosano Pharma Corporation since May 22, 2015, until May 10, 2022. He has been the Chief Executive Officer and Director of Regulus T...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7yrs | US$2.57m | 0.087% $ 99.7k | |
| Chief Financial Officer | 4.8yrs | US$1.07m | 0.0088% $ 10.1k | |
| Senior VP | 13.3yrs | US$1.09m | 0.015% $ 17.6k | |
| President | less than a year | no data | 0% $ 0 | |
| VP of Finance & Controller | 4.8yrs | no data | no data | |
| Senior Vice President of Clinical Operations | 1.5yrs | no data | no data | |
| Chief Medical Officer | 1.5yrs | no data | no data | |
| Vice President of Translational Medicine | no data | no data | no data |
4.8yrs
Average Tenure
54yo
Average Age
Experienced Management: 7RG0's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7yrs | US$2.57m | 0.087% $ 99.7k | |
| President | less than a year | no data | 0% $ 0 | |
| Independent Director | 11.1yrs | US$99.44k | 0.060% $ 68.2k | |
| Member of the Scientific Advisory Board | 5.2yrs | US$1.48m | no data | |
| Independent Chairman of the Board | 15.3yrs | US$131.44k | 1.49% $ 1.7m | |
| Chairman of the Scientific Advisory Board & Independent Director | 15.3yrs | US$95.44k | 0.0039% $ 4.5k | |
| Independent Director | 4.9yrs | US$97.44k | 0% $ 0 | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 7.9yrs | US$93.44k | 0.0027% $ 3.1k | |
| Independent Director | 6.1yrs | US$107.44k | 0.0042% $ 4.8k | |
| Independent Director | 6.9yrs | US$93.44k | 0.0072% $ 8.3k |
7.0yrs
Average Tenure
60yo
Average Age
Experienced Board: 7RG0's board of directors are considered experienced (7 years average tenure).